Serum levels of 2′, 5 oligoadenylate synthetase during interferon therapy in patients with B‐cell chronic lymphocytic leukemia

American Journal of Hematology

Volumn 43, Issue 1, 1993, Pages 1-4

  Musolino, C ^a   Grosso, P ^a   Alonci, A ^a   Allegra, A ^a   Orlando, A ^a   Cincotta, M ^a   Buda, G ^a   Squadrito, G ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

2 5 AS; clinical response; IFN alpha; sIL 2R

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; INTERLEUKIN 2 RECEPTOR; RECOMBINANT ALPHA2B INTERFERON;

AGED; ARTICLE; B CELL LEUKEMIA; BLOOD LEVEL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLUENZA; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

2',5'-OLIGOADENYLATE SYNTHETASE; AGED; DRUG MONITORING; HUMAN; INTERFERON ALFA-2B; LEUKEMIA, B-CELL, CHRONIC; NEOPLASM STAGING; RECEPTORS, INTERLEUKIN-2;

EID: 0027238316     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.2830430102     Document Type: Article

References (34)

1. Therapy of chronic myelogenous leukemia: Chemotherapy and interferons
2. Clinical investigation of human alpha interferon in chronic myelogenous leukemia
3. Interferon therapy of non Hodgkin's lymphoma
4. The role of interferon in the treatment of hairy cell leukemia
5. Treatment of hairy cell leukemia with recombinant DNA‐derived interferon alpha: A phase II study
6. Interferons in the treatment of multiple myeloma
7. Maintenance treatment with recombinant interferon alpha 2b in patients with multiple myeloma responding to conventional induction chemotherapy
8. Recombinant alpha 2b‐interferon therapy in untreated stages A and B chronic lymphocytic leukemia
9. Recombinant alpha 2 interferon in the treatment of B chronic lymphocylic leukemia in early stage
10. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia: A pilot study
11. Recombinant alpha‐2a interferon in treatment of B‐chronic lymphocytic leukemia. A preliminary report with emphasis on previously untreated patients in early stage of disease
12. Treatment of early stage B‐cell chronic lymphocytic leukemia with alpha interferon
13. Interferon alpha 2b therapy in untreated early stage, B‐chronic lymphocytic leukemia patients: One‐year follow‐up
14. Alpha‐2b interferon in the treatment of advanced chronic lymphocytic leukemia
15. Interferon therapy of lymphoproliferative disorders
16. Favorable response of early stage B CLL patients to treatment with IFN alpha 2
17. The relevance of animal models to the study of the antitumor activity of the interferons
18. Proliferative response of hairy cells to B cell growth factor (BCGF). In vivo inhibition by interferon alpha and in vitro effects of interferon alpha, beta and gamma
19. B cell lymphocytes and inhibition by type I interferon in vitro
20. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies
21. Tumour necrosis factor as an autocrine tumour growth factor for chronic B cell malignancies
22. Transcriptional induction by interferon
23. 2‐5A mediator in search of a function
24. Qualitative differences in effects of recombinant alpha, beta and gamma interferon on human peripheral blood leukocytes in vitro
25. Serum 2′,5′‐oligoadenylale synthetase activity during interferon treatment of chronic hepatitis B
26. Action of interferon alpha on hairy cell leukemia: Expression of specific receptors (2′‐5′) oligo (A) synthetase in tumour cells from sensitive and resistant patients
27. Alpha interferon therapy for haematological malignancies: Correlation between in vivo induction of the 2′,5′ oligoadenylate system and clinical response
28. Clinical staging of chronic lymphocytic leukemia
29. Possible mechanism of action of interferon alpha in chronic B cell malignancies
30. In vivo and in vitro induction of 2′‐5′ oligoadenylate synthetase by interferon‐alpha in nodular non‐Hodgkin's lymphoma and correlations with the clinical response
31. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha interferon: Correlation with receptor binding and induction of 2′5′‐oligoadenylate synthetase
32. Analysis of interferon‐inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon alpha treatment
33. The released interleukin 2 receptors bind interleukin 2 efficiently